Breakfast bites: Highlights from ADPD 2024™ | S1E2 – Springer Health+ IME: Podcast to Practice – Podcast

Episodes

New and emerging therapies in gMG: going upstream, T-cell and B-cell targeted therapies
16 Jun· Springer Health+ IME: Podcast to Practice
Dr. Kelly Gwathmey and Dr. Pushpa Narayanaswami discuss emerging B- and T-cell targeted therapies for gMG, highlighting recent clinical trials, mechanisms of action, and the evolving treatment paradigm.
- Listen Listen again Continue Playing...
- Listen later Listen later
New and emerging therapies in gMG: FcRn receptor antagonists and complement inhibition
16 Jun· Springer Health+ IME: Podcast to Practice
Dr. Kelly Gwathmey and Dr. Pushpa Narayanaswami discuss clinical evidence and practical considerations for integrating FcRn antagonists and complement inhibitors into the treatment of gMG.
- Listen Listen again Continue Playing...
- Listen later Listen later
Deep dive into targeted therapies: understanding IDH1-mutant AML treatments | S6E3
16 Jun· Springer Health+ IME: Podcast to Practice
Prof. Amer Zeidan and Prof. Courtney D. DiNardo discuss the mechanism of action, efficacy, and safety profiles of novel targeted therapies for IDH1-mutant R/R AML.
- Listen Listen again Continue Playing...
- Listen later Listen later
Understanding gMG
10 Jun· Springer Health+ IME: Podcast to Practice
Dr. Kelly Gwathmey and Dr. Sithara Ramdas discuss the clinical presentation, diagnostic challenges, and treatment considerations for both adult and juvenile myasthenia gravis.
- Listen Listen again Continue Playing...
- Listen later Listen later
Voices of gMG: enhancing patient-centric care
3 Jun· Springer Health+ IME: Podcast to Practice
Janel Worcester-Brown and Dr. Kelly Gwathmey engage in a compelling patient-physician discussion of the realities of living with gMG and the challenges patients face navigating their healthcare journey.
- Listen Listen again Continue Playing...
- Listen later Listen later
Advancing AML treatment: evidence-based regimens and guidelines for R/R AML management | S6E2
3 Jun· Springer Health+ IME: Podcast to Practice
Prof. Amer Zeidan and Dr. Eunice Wang discuss the latest evidence-based regimens and guideline updates for the clinical application of targeted therapy in R/R AML.
- Listen Listen again Continue Playing...
- Listen later Listen later
Unveiling the mysteries of molecular testing in AML: a guide for oncologists | S6E1
20 May· Springer Health+ IME: Podcast to Practice
Prof. Amer Zeidan and Dr. Sanam Loghavi discuss effective strategies for implementing molecular testing and overcoming barriers in clinical practice for R/R AML.
- Listen Listen again Continue Playing...
- Listen later Listen later
Key CGM Updates and Highlights From the 2025 Standards of Care in Diabetes Revision by the ADA | S3E4
17 Mar· Springer Health+ IME: Podcast to Practice
Dr. Jennifer Green shares exciting CGM device highlights from the 2025 Standards of Care in Diabetes revision by the ADA.
- Listen Listen again Continue Playing...
- Listen later Listen later
Importance of interdisciplinary working with the patient at the center | S5E5
7 Feb· Springer Health+ IME: Podcast to Practice
Watch Professor Tina Vilsbøll and patient, Molly Boll, discuss the importance and benefits of effective patient communication, and challenges of SDM in T2D and CKD management.
- Listen Listen again Continue Playing...
- Listen later Listen later
Real-world data on anti-amyloid antibody therapies | S1E9
13 Nov 2024· Springer Health+ IME: Podcast to Practice
Episode 9: Claire Paquet discusses the implications of the real-world and recommendation data presented on anti-amyloid antibody therapies for AD
- Listen Listen again Continue Playing...
- Listen later Listen later
Opportunities for anti-amyloid antibody treatment | S1E8
13 Nov 2024· Springer Health+ IME: Podcast to Practice
Episode 8: Juan Fortea comments on future opportunities for anti-amyloid antibody treament given the consolidation of clinical trial data in the real world
- Listen Listen again Continue Playing...
- Listen later Listen later
Key CGM Updates and Highlights from the EASD 2024 Conference | S3E3
3 Oct 2024· Springer Health+ IME: Podcast to Practice
Dr. Jennifer Green discusses breaking news and clinical implications of data presented at EASD 2024 on CGM technology use in type 2 diabetes.
- Listen Listen again Continue Playing...
- Listen later Listen later
The effects of time on blood-based biomarkers | S1E7
15 Aug 2024· Springer Health+ IME: Podcast to Practice
Petrice Cogswell summarizes research looking at temporal modelling of blood-based biomarkers and when to use them to predict brain amyloid deposition.
- Listen Listen again Continue Playing...
- Listen later Listen later
Is it too soon to use blood-based biomarkers for AD in primary care? | S1E6
5 Aug 2024· Springer Health+ IME: Podcast to Practice
Michelle Mielke discusses the current status for blood-based biomarker use in primary care in light of research presented at AAIC24.
- Listen Listen again Continue Playing...
- Listen later Listen later
Discussing the potential for blood based biomarker use | S1E5
5 Aug 2024· Springer Health+ IME: Podcast to Practice
Rik Ossenkoppele discusses the latest research presented on blood-based biomarkers, including their accuracy for diagnosing Alzheimer’s disease and when best to use them.
- Listen Listen again Continue Playing...
- Listen later Listen later
Advances in therapies that work across multiple disease disciplines | S5E4
18 Jul 2024· Springer Health+ IME: Podcast to Practice
Explore advances in therapies available for CKD in T2D and the clinical evidence and guidelines supporting their use with Professor Nilolaus Marx
- Listen Listen again Continue Playing...
- Listen later Listen later
Improving integration of guidelines for CKD in T2D in clinical practice | S5E3
18 Jul 2024· Springer Health+ IME: Podcast to Practice
Learn about evidence-based guidelines for management of CKD in T2D and how these can be integrated into clinical practice with Professor David Cherney
- Listen Listen again Continue Playing...
- Listen later Listen later
Improving recognition, diagnosis and classification of CKD in T2D | S5E2
18 Jul 2024· Springer Health+ IME: Podcast to Practice
Listen to Professor Pinar Topsever discuss the risk factors for CKD in T2D, how to recognise and diagnose CKD in patients with T2D, and the barriers to recognition and diagnosis in practice.
- Listen Listen again Continue Playing...
- Listen later Listen later
Overview of the diabetes-cardio-kidney spectrum and importance of proactive management | S5E1
18 Jul 2024· Springer Health+ IME: Podcast to Practice
Listen to Professor Tina Vilsbøll provide an overview of diabetic kidney disease (DKD) and the diabetes-cardio-kidney spectrum, as she discusses the importance of proactive identification and management.
- Listen Listen again Continue Playing...
- Listen later Listen later
Key CGM Updates and Highlights from the ADA 2024 Conference | S3E2
4 Jul 2024· Springer Health+ IME: Podcast to Practice
Dr. Eugene Wright, Jr. discusses breaking news and clinical implications of data presented at the ADA 2024 conference on CGM technology.
- Listen Listen again Continue Playing...
- Listen later Listen later
Show more

Episodes

New and emerging therapies in gMG: going upstream, T-cell and B-cell targeted therapies

New and emerging therapies in gMG: FcRn receptor antagonists and complement inhibition

Deep dive into targeted therapies: understanding IDH1-mutant AML treatments | S6E3

Understanding gMG

Voices of gMG: enhancing patient-centric care

Advancing AML treatment: evidence-based regimens and guidelines for R/R AML management | S6E2

Unveiling the mysteries of molecular testing in AML: a guide for oncologists | S6E1

Key CGM Updates and Highlights From the 2025 Standards of Care in Diabetes Revision by the ADA | S3E4

Importance of interdisciplinary working with the patient at the center | S5E5

Real-world data on anti-amyloid antibody therapies | S1E9

Opportunities for anti-amyloid antibody treatment | S1E8

Key CGM Updates and Highlights from the EASD 2024 Conference | S3E3

The effects of time on blood-based biomarkers | S1E7

Is it too soon to use blood-based biomarkers for AD in primary care? | S1E6

Discussing the potential for blood based biomarker use | S1E5

Advances in therapies that work across multiple disease disciplines | S5E4

Improving integration of guidelines for CKD in T2D in clinical practice | S5E3

Improving recognition, diagnosis and classification of CKD in T2D | S5E2

Overview of the diabetes-cardio-kidney spectrum and importance of proactive management | S5E1

Key CGM Updates and Highlights from the ADA 2024 Conference | S3E2